VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER Drug Patent Profile

When do Vaprisol In 5% Dextrose In Plastic Container patents expire, and when can generic versions of Vaprisol In 5% Dextrose In Plastic Container launch?

Vaprisol In 5% Dextrose In Plastic Container is a drug marketed by Cumberland and is included in one NDA.

The generic ingredient in VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER is conivaptan hydrochloride. Additional details are available on the conivaptan hydrochloride profile page.

Summary for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	16
DailyMed Link:	VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Jesse Corry	Phase 1
University of Florida	Phase 2
Rigshospitalet, Denmark	Phase 4

See all VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER clinical trials

US Patents and Regulatory Information for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cumberland	VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER	conivaptan hydrochloride	INJECTABLE;INTRAVENOUS	021697-002	Oct 8, 2008		RX	Yes	Yes

Expired US Patents for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cumberland	VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER	conivaptan hydrochloride	INJECTABLE;INTRAVENOUS	021697-002	Oct 8, 2008	5,723,606

International Patents for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

See the table below for patents covering VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2453123	DERIVE CONDENSE DE LA BENZAZEPINE; COMPOSITIONS PHARMACEUTIQUES A BASE DE CE DERIVE (INTERMEDIATE FOR CONDENSED BENZAZEPINE DERIVATIVES)
Canada	2167673	DERIVE CONDENSE DE LA BENZAZEPINE; COMPOSITIONS PHARMACEUTIQUES A BASE DE CE DERIVE (CONDENSED BENZAZEPINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF)
China	1040210

Market Dynamics and Financial Trajectory for VAPRISOL in 5% Dextrose in Plastic Container

Last updated: July 29, 2025

Introduction

VAPRISOL, formulated as a solution of 5% dextrose in a plastic container, occupies a critical niche within intravenous (IV) hydration and nutrition markets. Its primary application lies in providing essential fluids and glucose to patients requiring parenteral nutrition, electrolyte balance, or fluid replacement. As healthcare systems evolve and demand for hospital-based infusion therapies increases, understanding the market dynamics and financial trajectory for VAPRISOL is crucial for manufacturers, investors, and healthcare providers aiming to capitalize on this segment.

Market Landscape and Demand Drivers

Growing Hospitalization Rate and Parenteral Nutrition Needs

The global increase in hospitalization rates, driven by chronic conditions and acute illnesses, fuels demand for IV fluids like VAPRISOL. The rising prevalence of diabetes, especially in aging populations, necessitates glucose solutions for metabolic management, thereby expanding the need for dextrose products [1]. Moreover, the expansion of outpatient infusion services and home health care further broadens the usage scope.

Shift Toward Plastic Container Packaging

The transition from glass to plastic containers aligns with modern safety standards and convenience. Plastic containers reduce breakage risk, ease handling, and extend shelf life, thus broadening the distribution channel and reducing patient and healthcare provider risks. Regulatory agencies increasingly favor plastic over glass, particularly in sterile, hospital-use medications [2].

Advances in Intravenous Therapy and Modern Infusion Devices

Technological advances in infusion pumps and sterile delivery systems augment the safe administration of solutions like VAPRISOL. These innovations improve patient safety and compliance, simultaneously driving market expansion.

Regulatory and Quality Assurance Trends

Stringent regulatory standards, particularly for sterilization and endotoxin control, influence manufacturing protocols. Companies investing in compliance and quality assurance can command premium pricing and foster brand loyalty. Data on regulatory approvals and adherence further influence buyer confidence.

Competitive Landscape

Key Players and Market Share

Major pharmaceutical manufacturers such as Baxter International, B. Braun Melsungen AG, and Pfizer dominate the global IV fluids market, including dextrose solutions. These firms leverage extensive distribution networks, R&D capabilities, and regulatory expertise to sustain market leadership [3].

Product Differentiation and Innovation

Differentiation strategies—such as preservative-free formulations, improved stability, and environmentally friendly packaging—enhance competitive edge. Customized formulations catering to specific patient populations (pediatric, neonatal) also open niche markets.

Pricing Dynamics

Pricing strategies are influenced by raw material costs, manufacturing expenses, regulatory compliance costs, and competitive pressure. Volume discounts, contract-based pricing with healthcare institutions, and bundling services impact revenue streams.

Market Challenges and Opportunities

Cost Fluctuations in Raw Materials

Ingredients such as dextrose and plastics are subject to volatile commodity prices, impacting profit margins. Suppliers' capacity constraints and geopolitical factors further exacerbate cost instability.

Regulatory Hurdles and Compliance

Stringent standards, differing across regions, impose time-consuming approval processes and compliance costs, especially in emerging markets. Navigating these challenges requires strategic planning and resource allocation.

Growing Trends: Personalized Medicine and Biocompatible Solutions

The shift toward personalized nutrition and biocompatible, additive-free solutions poses both a challenge and an opportunity. Companies investing in these domains can differentiate their offerings and enter high-margin segments.

Financial Trajectory: Market Forecast and Revenue Projections

Market Size and Growth Rate

The global IV fluids market, including dextrose solutions, is expected to grow at a compound annual growth rate (CAGR) of approximately 4-6% over the next five years, driven by rising healthcare expenditures and expanding hospitalization needs [4].

Revenue Trends for VAPRISOL

Given its positioning, VAPRISOL’s revenue trajectory aligns with the broader market growth, with potential accelerations driven by new healthcare infrastructure, especially in developing economies. Premium pricing may be achievable through differentiating attributes and superior quality standards.

Investment and R&D Considerations

To sustain growth, companies should allocate R&D budgets toward innovation in container design, formulation stability, and integration with smart infusion systems. Collaboration with healthcare providers can lead to tailored solutions and expanded market penetration.

Strategic Expansions

Regional expansion into emerging markets and strategic partnerships with healthcare providers could significantly enhance revenue streams. Local manufacturing facilities can reduce costs and improve supply chain resilience.

Economic and Regulatory Impact on Financial Outcomes

Price Regulation and Reimbursement Policies

Government policies and reimbursement schemes influence profitability. In regions with government-controlled drug pricing or strict reimbursement criteria, revenue growth may be constrained. Conversely, high-income markets with favorable reimbursement can maximize margins.

Patent and Market Exclusivity Challenges

Patent expirations and generic competition pose risks. Securing data exclusivity and protecting proprietary formulations are vital to maintaining market share and profitability.

Key Market Segments and Revenue Opportunities

• Hospital End-Use: Largest volume, stable demand.
• Outpatient and Home Care: Growing segment for IV hydration solutions.
• Niche Markets: Pediatric, neonatal, and specialty formulations command premium pricing.

Strategic Outlook and Investment Recommendations

Investors and companies should focus on R&D for product differentiation, strategic regional expansion, and building robust supply chains. Emphasizing quality assurance and regulatory compliance will solidify market position and enable premium pricing.

Key Takeaways

• The demand for VAPRISOL in 5% dextrose solution is closely tied to global hospitalization rates, diabetes prevalence, and advancements in infusion therapy technology.
• The shift toward plastic containers enhances safety profiles and market accessibility, fostering growth opportunities.
• Competition is intensifying, with key players innovating in packaging, formulation, and distribution channels.
• Market growth estimates suggest a CAGR of 4-6%, driven by healthcare infrastructure expansion and aging populations.
• Strategic investments in R&D, regional expansion, and regulatory compliance are critical for sustaining long-term profitability.

FAQs

1. What are the primary drivers behind the demand for VAPRISOL in various markets?
   Increasing hospitalization rates, the prevalence of metabolic disorders, technological advances in infusion therapy, and safety benefits of plastic containers drive demand globally.

2. How does packaging transition impact market competitiveness?
   The move from glass to plastic containers improves safety, reduces costs, and expands distribution, offering manufacturers competitive advantages.

3. What are the key challenges faced by manufacturers of VAPRISOL?
   Volatile raw material costs, regulatory hurdles, and intense competition from generics pose ongoing challenges.

4. Which regions are anticipated to exhibit the highest growth for VAPRISOL?
   Emerging markets in Asia-Pacific and Latin America are projected to show significant growth due to expanding healthcare infrastructure and investments.

5. How can companies maximize profitability in the VAPRISOL market?
   By investing in innovation, ensuring regulatory compliance, expanding regional presence, and developing value-added formulations.

---

Sources:

[1] Market Research Future, "Global Intravenous Solutions Market," 2022.
[2] Pharmaceutical Packaging Review, "Trends in IV Container Materials," 2021.
[3] IQVIA, "Global IV Fluids Market Insights," 2022.
[4] Statista, "Projected Growth of the Global IV Fluids Market," 2023.